Repligen Co. to Post Q3 2024 Earnings of $0.42 Per Share, William Blair Forecasts (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Equities research analysts at William Blair raised their Q3 2024 EPS estimates for Repligen in a report issued on Thursday, May 2nd. William Blair analyst M. Larew now expects that the biotechnology company will earn $0.42 per share for the quarter, up from their prior forecast of $0.38. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. William Blair also issued estimates for Repligen’s Q4 2024 earnings at $0.47 EPS, FY2024 earnings at $1.46 EPS and FY2025 earnings at $2.24 EPS.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter in the prior year, the company posted $0.64 EPS. The business’s revenue for the quarter was down 17.1% on a year-over-year basis.

Several other equities analysts also recently issued reports on the stock. KeyCorp upped their price objective on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. cut their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Stifel Nicolaus lifted their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $197.75.

Repligen Trading Up 0.4 %

Repligen stock opened at $167.05 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 6.35. The stock has a market cap of $9.33 billion, a PE ratio of 668.23, a price-to-earnings-growth ratio of 5.46 and a beta of 1.03. The stock has a 50-day moving average of $180.81 and a two-hundred day moving average of $174.32. Repligen has a one year low of $110.45 and a one year high of $211.13.

Hedge Funds Weigh In On Repligen

Institutional investors and hedge funds have recently modified their holdings of the business. YHB Investment Advisors Inc. purchased a new position in Repligen during the first quarter worth approximately $26,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares during the period. Principal Securities Inc. purchased a new position in shares of Repligen during the 4th quarter valued at approximately $48,000. Signaturefd LLC grew its stake in Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 86 shares during the period. Finally, CWM LLC increased its holdings in Repligen by 19.9% in the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Repligen news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,597 shares of company stock valued at $5,039,532. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.